The use of azathioprine in Crohns disease during pregnancy and in the post-operative setting: A worldwide survey of experts

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 6, 2011, Pages 707-713

  Peyrin Biroulet, L ^a,b   Oussalah, A ^a,b   Roblin, X ^c   Sparrow, M P ^d  

^a INSERM   (France)

^b UNIVERSITY HOSPITAL OF NANCY   (France)

^c UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^d ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CROHN DISEASE; DELIVERY; DISEASE SEVERITY; DRUG USE; FEMALE; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; INTERNET; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; PHYSICIAN ATTITUDE; POSTOPERATIVE PERIOD; PREGNANCY; PREGNANT WOMAN; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; REMISSION; DRUG UTILIZATION; EPIDEMIOLOGY; HEALTH PERSONNEL ATTITUDE; METHODOLOGY; POSTOPERATIVE CARE; RECURRENT DISEASE; STATISTICS;

ATTITUDE OF HEALTH PERSONNEL; AZATHIOPRINE; CROHN DISEASE; DRUG UTILIZATION; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; POSTOPERATIVE CARE; PREGNANCY; RECURRENCE;

EID: 79951673891     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04577.x     Document Type: Article

References (21)

1. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W,. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130: 935-9. (Pubitemid 43374542)
2. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G,. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 47-53. (Pubitemid 41820634)
3. Pearson DC, May GR, Fick G, Sutherland LR,. Azathioprine for maintaining remission of Crohns disease. Cochrane Database Syst Rev 2000; 2: CD000067.
4. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R,. A controlled double blind study of azathioprine in the management of Crohns disease. Gut 1995; 37: 674-8.
5. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F,. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohns disease. Gastroenterology 2000; 119: 895-902.
6. Sandborn WJ,. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91: 423-33. (Pubitemid 126733803)
7. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohns disease: a meta-analysis. Am J Gastroenterol 2009; 104: 2089-96.
8. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohns disease: special situations. J Crohns Colitis 2010; 4: 63-101.
9. Platzek T, Bochert G,. Dose-response relationship of teratogenicity and prenatal-toxic risk estimation of 6-mercaptopurine riboside in mice. Teratog Carcinog Mutagen 1996; 16: 169-81. (Pubitemid 27033229)
10. Mosesso P, Palitti F,. The genetic toxicology of 6-mercaptopurine. Mutat Res 1993; 296: 279-94. (Pubitemid 23063747)
11. Meuwissen SG, Ewe K, Gassull MA, et al. IOIBD questionnaire on the clinical use of azathioprine, 6-mercaptopurine, cyclosporin A and methotrexate in the treatment of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2000; 12: 13-8. (Pubitemid 30072099)
12. DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
13. Polifka JE, Friedman JM,. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 2002; 65: 240-61. (Pubitemid 34492613)
14. Mahadevan U, Kane S,. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006; 131: 283-311. (Pubitemid 44015759)
15. Goldstein LH, Dolinsky G, Greenberg R, et al. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 2007; 79: 696-701. (Pubitemid 47584193)
16. Langagergaard V, Pedersen L, Gislum M, Norgard B, Sorensen HT,. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther 2007; 25: 73-81. (Pubitemid 44902866)
17. Norgard B, Pedersen L, Christensen LA, Sorensen HT,. Therapeutic drug use in women with Crohns disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007; 102: 1406-13. (Pubitemid 46976292)
18. Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME study. Gut 2011; 60: 198-203.
19. Ahmed T, Rieder F, Fiocchi C, Achkar JP,. Pathogenesis of postoperative recurrence in Crohns disease. Gut 2010 [Epub ahead of print].
20. Reinisch W, Angelberger S, Petritsch W, et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohns disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010; 59: 752-9.
21. Jharap B, Seinen ML, de Boer NK, et al. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm Bowel Dis 2010; 16: 1541-9.